Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biodelivery Sci Intl (BDSI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 157,834
  • Shares Outstanding, K 59,560
  • Annual Sales, $ 61,990 K
  • Annual Income, $ 5,290 K
  • 36-Month Beta 0.38
  • Price/Sales 2.55
  • Price/Cash Flow N/A
  • Price/Book 3.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.14
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.19
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +10.64%
on 08/03/18
2.97 -12.61%
on 07/20/18
-0.30 (-10.34%)
since 07/13/18
3-Month
1.90 +36.84%
on 05/16/18
3.20 -18.75%
on 06/25/18
+0.65 (+33.33%)
since 05/15/18
52-Week
1.70 +52.94%
on 05/11/18
3.42 -24.09%
on 08/17/17
-0.60 (-18.75%)
since 08/15/17

Most Recent Stories

More News
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA(R)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain today announced that a leading U.S. pharmacy...

BDSI : 2.60 (-1.89%)
BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down

BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.

ENDP : 15.41 (-4.29%)
BDSI : 2.60 (-1.89%)
AGN : 184.61 (+0.08%)
TEVA : 21.85 (-1.22%)
BioDelivery Sciences International (BDSI) Reports Q2 Loss, Misses Revenue Estimates

BioDelivery (BDSI) delivered earnings and revenue surprises of 15.79% and -2.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

BDSI : 2.60 (-1.89%)
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results

BELBUCA Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter

BDSI : 2.60 (-1.89%)
BioDelivery Sciences International, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 9, 2018 / BioDelivery Sciences International, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30...

BDSI : 2.60 (-1.89%)
Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More

Several drug/biotech companies are set to report second-quarter results on Aug 9. Let's see how things are shaping up for their announcements.

BDSI : 2.60 (-1.89%)
PBYI : 42.40 (-5.46%)
LOXO : 158.07 (-1.00%)
PRGO : 68.39 (-1.53%)
What's in the Cards for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) product purchases and introductions in the Rx segment are expected to boost sales.

AZN : 38.43 (-1.41%)
BDSI : 2.60 (-1.89%)
SCYX : 1.30 (-2.26%)
PRGO : 68.39 (-1.53%)
What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?

On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.

ACIU : 8.77 (-2.77%)
BDSI : 2.60 (-1.89%)
PBYI : 42.40 (-5.46%)
DNLI : 15.04 (-0.07%)
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders...

EYEG : 0.52 (unch)
BDSI : 2.60 (-1.89%)
What's in the Cards for Inovio (INO) This Earnings Season?

During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.

ACIU : 8.77 (-2.77%)
BDSI : 2.60 (-1.89%)
DNLI : 15.04 (-0.07%)
INO : 4.41 (-1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade BDSI with:

Business Summary

BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any...

See More

Key Turning Points

2nd Resistance Point 2.78
1st Resistance Point 2.72
Last Price 2.60
1st Support Level 2.57
2nd Support Level 2.48

See More

52-Week High 3.42
Fibonacci 61.8% 2.77
Last Price 2.60
Fibonacci 50% 2.56
Fibonacci 38.2% 2.36
52-Week Low 1.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar